A new medication can have impressive clinical trial results and still face one of the hardest questions in healthcare: is it worth paying for?
That question becomes even more important when a therapy costs tens of thousands of dollars per year, enters a crowded treatment category, or could affect a large population. Health plans and pharmacy benefit managers need more than an explanation of how the drug works. They need to understand which patients benefit, how the therapy compares with existing options, what it could do to healthcare utilization, and what the financial impact may look like across an entire population.
There is a pharmaceutical-industry career built around helping answer those questions.
Alumis currently has a field-based Medical Outcomes Liaison position open in the United States. The company specifically lists PharmD among the advanced degrees that qualify candidates for the role. The liaison works with payers, PBMs, health systems, and other healthcare decision-makers to communicate the clinical and economic value of Alumis therapies. Responsibilities include presenting clinical evidence, real-world evidence, and health-economic data while supporting formulary access, reimbursement strategy, and broader evidence-generation planning.
The pharmacist is not primarily explaining a medication to one patient or one prescriber.
They are helping organizations decide what a therapy is worth across thousands or millions of patients.
A payer asks different questions about a medication
Consider a hypothetical new therapy that costs $100,000 per patient each year.
A physician may focus first on whether the treatment works for the patient sitting in front of them. They will consider efficacy, safety, contraindications, dosing, and how the new therapy compares with other clinical options.
A health plan has to ask those questions too, but it cannot stop there.
The payer also needs to estimate how many members may qualify for treatment. Leaders want to know whether the therapy could reduce hospitalizations, procedures, or other medical costs. They need to understand whether the clinical trials included patients who resemble their population and whether real-world evidence supports what researchers saw during development.
Then come the economic questions.
What happens to the plan’s budget if 2,000 members become eligible? How does the therapy compare with the current standard of care? Should coverage require prior authorization? Where should the product sit on the formulary? Are there specific patients for whom the value proposition looks much stronger?
Those are medication questions and business questions at the same time.
That intersection creates room for a PharmD.
The job is to translate evidence into value
Alumis describes its Medical Outcomes Liaison as a Medical Affairs professional who translates clinical and HEOR evidence into value narratives that population-based healthcare decision-makers can use. The role builds relationships with payers, PBMs, and health systems while supporting both pre-launch and launch activities.
That phrase, value narrative, is important.
A clinical trial may show that a drug improves an endpoint. The liaison needs to help explain why that improvement matters to the organization responsible for covering treatment.
Suppose a therapy reduces disease flares. The clinical story centers on the reduction in flares and the safety profile.
The value story goes further.
Could fewer flares reduce emergency visits or hospitalizations? Could patients remain productive longer? Does another medication already produce similar results at a lower cost? Which subgroup appears to receive the greatest benefit? What uncertainties remain?
The liaison does not invent answers to those questions. The role communicates the available evidence accurately and helps healthcare decision-makers understand how it applies to their populations.
That requires much more than memorizing a slide deck.
This is where HEOR becomes important
One of the most useful terms for pharmacists to learn is HEOR, or Health Economics and Outcomes Research.
Traditional clinical research often asks whether a therapy is safe and effective.
HEOR asks additional questions about value, outcomes, resource use, quality of life, and cost.
Imagine two medications that both improve the same disease. One requires fewer hospital visits. Another has a lower acquisition cost. One may work particularly well in a high-risk population, while the other has broader evidence.
Which product creates greater value?
There may not be one universal answer.
The answer can depend on the population, perspective, costs included in the analysis, time horizon, and outcomes being measured.
That is why health plans need evidence beyond the mechanism of action and pivotal trial.
Alumis expects its Medical Outcomes Liaison to understand HEOR, real-world evidence, and the U.S. payer landscape. The liaison also contributes to HEOR and evidence-generation plans, meaning insights from payer conversations can help the company understand which evidence decision-makers still need.
The communication therefore works in both directions.
Real-world evidence helps answer what happens after the trial
Randomized trials remain essential, but health plans often want to know what happens once treatment enters routine practice.
Do patients remain on therapy?
Does adherence look different outside a controlled study?
Which patients actually receive the medication?
What healthcare resources do they use before and after treatment?
Are the outcomes similar across different populations?
Real-world evidence can help answer some of those questions.
A Medical Outcomes Liaison may bring that information into conversations with healthcare decision-makers alongside traditional clinical evidence and health-economic analyses. Alumis specifically includes real-world evidence among the types of information its liaison will communicate.
This is another reason pharmacists can fit well in the role.
A PharmD brings experience thinking about what medications do after they leave the controlled environment of a study.
Clinical evidence tells part of the story.
Medication use in actual healthcare settings can tell another part.
The liaison needs to understand both.
The formulary is where science becomes a coverage decision
Most pharmacists know what a formulary is.
Fewer are shown the industry careers built around influencing how formulary decision-makers evaluate evidence.
When a payer considers a new product, the decision is rarely as simple as deciding whether the drug works. The organization may examine comparative efficacy, safety, treatment guidelines, unmet need, utilization, cost, budget impact, patient population, and other available evidence.
The result can affect coverage restrictions, prior authorization requirements, preferred status, and patient access.
That is one reason Medical Outcomes Liaison roles sit close to both Medical Affairs and Market Access.
Alumis says its liaison supports formulary access and reimbursement while gathering payer insights that can inform broader company strategy.
The pharmacist therefore becomes a bridge.
On one side sits the science behind the therapy.
On the other side sits the organization deciding whether and how to pay for it.
An AMCP dossier is one of the tools behind these conversations
Another term worth learning is AMCP dossier.
The Academy of Managed Care Pharmacy describes its Format for Formulary Submissions as a standardized way for manufacturers to organize clinical and economic evidence for healthcare decision-makers evaluating medical products. The dossier can include clinical evidence, economic models, budget impact, real-world evidence, and other information that supports coverage and formulary review.
In October 2026, AMCP released Format 6.0. The updated framework includes new guidance for biosimilars and cell and gene therapies, along with revised economic-modeling recommendations.
Alumis specifically lists AMCP dossier support among the Medical Outcomes Liaison’s responsibilities.
That is another useful clue for pharmacists studying this career.
A liaison is not simply traveling around discussing products.
The role sits inside a larger evidence ecosystem that includes HEOR teams, Medical Affairs, Market Access, real-world evidence, economic modeling, formulary strategy, and payer engagement.
Understanding that ecosystem makes the career much easier to see.
This is not quite the same job as an MSL
Many pharmacists know the Medical Science Liaison role.
Medical Outcomes Liaison is related, but the audience and conversation can look different.
An MSL often develops scientific relationships with physicians, researchers, and other external experts. Discussions may focus heavily on disease science, clinical trials, new evidence, unmet need, and research.
An outcomes or value liaison often spends more time with health plans, PBMs, integrated health systems, and other population-level decision-makers.
The question changes accordingly.
The MSL may spend more time discussing what the evidence says about the therapy.
The outcomes liaison also needs to explain what that evidence could mean for coverage, healthcare utilization, economic value, and the population a payer manages.
There is overlap between the roles, and companies structure their teams differently. Still, the distinction gives pharmacists another branch of Medical Affairs to explore.
If you like science but also find healthcare economics, managed care, and formulary strategy interesting, this side of the industry may fit differently from a traditional MSL career.
Amgen shows that this is a broader career neighborhood
Alumis is not the only company hiring for this type of work.
Amgen currently has a Medical Value and Access Liaison role within Medical Affairs. The company lists PharmD as a preferred qualification and asks the liaison to engage payer and integrated health-system accounts around therapeutic outcomes, economic outcomes, utilization, evidence-based medicine, prior authorization, reimbursement, and coverage policy.
The role also involves health economics opinion leaders, pharmacoeconomic information, population health, and payer policy. Amgen lists an annual U.S. salary range of $174,186 to $201,183, with actual compensation depending on factors such as experience and qualifications.
That helps establish that this is not one unusual job posting.
Different companies may use titles such as Medical Outcomes Liaison, Medical Value and Access Liaison, HEOR Liaison, Value & Evidence Liaison, or other variations.
The common function is more important than the title.
These professionals help connect medical evidence with decisions about access and value.
The PharmD matters because numbers still need clinical context
Imagine an economic model showing that one medication costs more than another.
That alone tells you very little.
Does the more expensive treatment work better? Does it prevent an outcome that costs much more later? Does it serve patients who have no alternative? Does it require less monitoring? Does it reduce hospital use?
The reverse is also true.
A therapy can produce a statistically impressive clinical result without automatically producing enough additional value to justify any price.
Someone has to understand both sides.
A PharmD can bring clinical context to the economic discussion.
Pharmacists understand therapeutic alternatives, patient populations, medication safety, disease progression, adherence, and the limitations of clinical evidence. With additional training in health economics and payer strategy, that knowledge can help them evaluate what a therapy means beyond the individual prescription.
This is domain expertise at a different scale.
The pharmacist is still interpreting medications.
The audience has changed.
Communication may be one of the most important skills
A Medical Outcomes Liaison can understand every study and still struggle in the role if they cannot communicate clearly.
The audience may include pharmacy directors, medical directors, population-health leaders, formulary decision-makers, economists, and other executives.
Those stakeholders do not need every detail from every clinical trial.
They need the information that helps answer their specific question.
A payer may care about which population benefited. Another stakeholder may want to understand budget impact. A health system could focus on hospital utilization or care pathways.
The liaison has to understand the audience, interpret the evidence, and communicate it without distorting the science.
Alumis specifically asks for someone who can translate complex data into clear, payer-relevant value insights. Amgen similarly emphasizes presentations around medical value, economic outcomes, utilization, pharmacoeconomics, and reimbursement policy.
That translation skill is difficult to automate completely.
Data can be generated quickly.
Knowing which data matter to a particular decision remains valuable.
This is another career where the PharmD alone is not enough
The job postings also provide an important reality check.
Alumis requires at least five years of experience in Medical Affairs, HEOR, Market Access, or a related field. Experience working directly with payers or other healthcare decision-makers is strongly preferred. The job also requires substantial travel, with the posting estimating roughly 50% to 75%.
Amgen’s preferred background includes biotech industry experience with U.S. payer accounts and deep knowledge of managed markets, reimbursement, pharmacoeconomics, population health, and patient access.
These are not typically direct transitions from a traditional community pharmacy role.
That does not make the career irrelevant.
It makes the job description useful.
Instead of seeing an unfamiliar role and asking whether you qualify today, you can use it to understand what experience the market rewards.
That turns the posting into a career map.
There are several possible bridges into value and outcomes work
A pharmacist working in managed care may already have exposure to formulary management, utilization management, payer strategy, and population-level medication decisions.
Someone in specialty pharmacy may understand high-cost therapies, access barriers, payer requirements, and complex patient journeys.
Medical Affairs experience can build scientific communication skills. HEOR roles can provide direct exposure to economic modeling, outcomes research, and evidence generation.
Market Access can teach how pricing, reimbursement, coverage, and payer strategy affect whether patients ultimately receive a medication.
Pharmaceutical fellowships also remain a common entry route for pharmacists early in their careers, particularly for Medical Affairs, HEOR, and Market Access.
There is no single path.
The more useful approach is to examine several job descriptions and identify which experiences appear repeatedly.
Those repeated skills reveal the bridge.
Start learning the language before trying to change careers
If this career interests you, begin with a handful of terms.
Learn what HEOR means. Understand the difference between real-world data and real-world evidence. Learn basic pharmacoeconomic concepts and how health plans evaluate budget impact.
Study managed care and formulary decision-making.
Then explore the AMCP Format for Formulary Submissions.
AMCP says its dossier framework exists to help healthcare decision-makers assess the clinical and economic value of medical products and understand their potential budget impact.
You do not need to become an expert in every area immediately.
The goal is to understand how the pieces connect.
A manufacturer generates evidence.
HEOR teams study value and outcomes.
Real-world evidence teams examine what happens outside traditional trials.
Market Access works on coverage and reimbursement.
Medical Affairs communicates science.
Payers use that information to make decisions.
The Medical Outcomes Liaison operates across several of those boundaries.
Once you see the system, the job title stops looking mysterious.
The career also changes how you think about medication value
Pharmacy school teaches pharmacists to evaluate whether a medication is appropriate.
That remains fundamental.
But healthcare organizations also need to decide whether a therapy creates enough value to justify its cost across a population.
Those are related questions, not identical ones.
A therapy may be clinically effective but expensive. Another may cost more upfront while reducing costly complications later. A new treatment could provide major value for a narrow subgroup but limited incremental benefit for another population.
That is why value cannot be reduced to price alone.
The Medical Outcomes Liaison helps communicate the evidence that allows healthcare decision-makers to examine that broader picture.
For pharmacists, this opens another way to use therapeutic knowledge.
You are not only deciding whether the medication makes sense.
You are helping someone understand what the medication means for an entire healthcare system.
Search the function, not only “pharmacist jobs”
Spend some time this week searching Medical Outcomes Liaison, Medical Value Liaison, HEOR Liaison, Medical Value and Access, and Value & Evidence.
Then compare those positions with Medical Science Liaison roles.
Look at who each role speaks with.
Notice what evidence they discuss. Pay attention to how often you see HEOR, real-world evidence, market access, payer strategy, pharmacoeconomics, formulary support, and AMCP dossiers.
Then identify one skill that appears repeatedly but does not currently exist on your résumé.
Maybe it is managed-care experience.
Perhaps it is HEOR.
It could be scientific presentations, payer engagement, real-world evidence, or pharmacoeconomics.
That gap becomes useful information.
You now have something specific to build toward instead of simply saying you want to work in the pharmaceutical industry.
A PharmD can help answer a very expensive question
The most interesting part of this career is the scale of the decision.
A pharmacist in traditional practice may help determine whether a medication is right for one patient.
A Medical Outcomes Liaison can help a health plan understand whether that same therapy creates enough clinical and economic value to cover across an entire population.
The decision can affect thousands of patients and millions of dollars.
That is a very different form of PharmD leverage.
The pharmacist still needs to understand the mechanism, clinical trials, safety, and place in therapy.
But now they also need to understand real-world evidence, healthcare economics, reimbursement, formularies, and payer priorities.
Clinical medicine meets healthcare strategy.
That is the opportunity.
A PharmD does not only have value because pharmacists understand which drug to use.
In another part of healthcare, that same knowledge can help answer a different question:
What is this therapy worth, and why should a healthcare system pay for it?
Resources & Citations
- Alumis Inc. “Medical Outcomes Liaison.” Current U.S. job posting. Alumis describes the position as a field-based Medical Affairs role that works with payers, PBMs, health systems, and other healthcare decision-makers. Responsibilities include communicating clinical, real-world, and health-economic evidence; supporting formulary access and payer strategy; contributing to HEOR and evidence-generation plans; and supporting AMCP dossiers. The role requires an advanced degree including PharmD and at least five years of relevant experience.
- BioSpace. “Medical Outcomes Liaison, Alumis Inc.” Posted October 30, 2026. BioSpace’s listing confirms the role’s Medical Affairs, Market Access, and HEOR focus and its responsibility for communicating clinical and economic value to healthcare decision-makers.
- Amgen. “Medical Value and Access Liaison, Central U.S.” Current Medical Affairs posting. The role includes payer and formulary support, pharmacoeconomic communication, reimbursement and coverage discussions, HEOR relationships, population health, and scientific exchange with payer and integrated health-system accounts. PharmD is listed as a preferred qualification. The posted U.S. salary range is $174,186 to $201,183.
- Academy of Managed Care Pharmacy. “AMCP Format for Formulary Submissions.” AMCP describes the dossier as a standardized framework for communicating clinical and economic evidence to healthcare decision-makers evaluating coverage, formulary placement, reimbursement, and payment.
- Academy of Managed Care Pharmacy. “AMCP Publishes Format 6.0.” October 23, 2026. Version 6.0 adds updated guidance for biosimilars, cell and gene therapies, and economic modeling while continuing to support communication of clinical and economic value between manufacturers and healthcare decision-makers.